(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
07 October 2021 (07.10.2021)

WIPO | PCT

(10) International Publication Number
WO 2021/202981 A1

(51) International Patent Classification:
*A61K 31/166* (2006.01) *A61K 9/00* (2006.01)
*A61K 31/4375* (2006.01) *A61P 35/00* (2006.01)

(21) International Application Number:
PCT/US2021/025551

(22) International Filing Date:
02 April 2021 (02.04.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/005,153 03 April 2020 (03.04.2020) US

(71) Applicants: **BEIGENE, LTD.** [US/US]; 2955 Campus Drive, Suite 200, San Mateo, California 94403 (US). **SPRINGWORKS THERAPEUTICS, INC.** [US/US]; 100 Washington Boulevard, Stamford, Connecticut 06902 (US).

(72) Inventors: **LUO, Lusong**; c/o BeiGene, Ltd., 2955 Campus Drive, Suite 200, San Mateo, California 94403 (US). **TANG, Zhiyu**; c/o BeiGene, Ltd., 2955 Campus Drive, Suite 200, San Mateo, California 94403 (US). **EDRIS, Badreddin**; c/o SpringWorks Therapeutics, Inc., 100 Washington Boulevard, Stamford, Connecticut 06902 (US). **SHEARER, Todd Webster**; c/o SpringWorks Therapeutics, Inc., 100 Washington Boulevard, Stamford, Connecticut 06902 (US).

(74) Agent: **GILLENTINE, Marsha Rose** et al.; Sterne, Kessler, Goldstein & Fox P.L.L.C., 1100 New York Avenue, NW, Washington, District of Columbia 20005 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

**Published:**
— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

WO 2021/202981 A1

(54) Title: CO-ADMINISTRATION OF MIRDAMETINIB AND LIFIRAFENIB FOR USE IN TREATING CANCERS

(57) Abstract: The present disclosure relates to methods of treating cancers comprising coadministration of mirdametinib or a pharmaceutically acceptable salt form thereof, and lifirafenib or a pharmaceutically acceptable salt form thereof, to a patient in need thereof. Also disclosed are pharmaceutical compositions of mirdametinib or a pharmaceutically acceptable salt form thereof, and lifirafenib or a pharmaceutically acceptable salt form thereof, for use in such cancer treatment, as well as uses of these compounds for manufacture of medicaments for the treatment of cancers.